Aarey Drugs & Pharmaceuticals Ltd. (IN:AAREYDRUGS)

:AAREYDRUGS

AAREYDRUGS

Aarey Drugs & Pharmaceuticals Ltd.

RESEARCH TOOLSreports

Want to see IN:AAREYDRUGS full AI Analyst Report?

Aarey Drugs & Pharmaceuticals Ltd. (AAREYDRUGS) Price & Analysis

0 Followers

AAREYDRUGS Stock Chart & Stats

₹68.03

-₹1.15(-1.99%)

At close: Jan 09 4:00 PM EST

₹68.03

-₹1.15(-1.99%)

Day’s Range― - ―

52-Week Range₹50.31 - ₹100.00

Previous CloseN/A

Volume4.04K

Average Volume (3M)7.61K

Market Cap

₹2.18B

Enterprise Value₹2.65B

Total Cash (Recent Filing)₹81.90M

Total Debt (Recent Filing)₹507.79M

Price to Earnings (P/E)48.7

Beta1.50

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.27

Shares Outstanding28,354,303

10 Day Avg. Volume5,578

30 Day Avg. Volume7,610

Financial Highlights & Ratios

PEG Ratio-13.05

Price to Book (P/B)0.96

Price to Sales (P/S)0.31

P/FCF Ratio-6.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sustained ProfitabilityThe company remains consistently profitable (net income ~39.7M in 2026) despite volatility. Persistent positive earnings support ongoing operations, help retain investor and creditor confidence, and provide a baseline for reinvestment or debt servicing over the medium term.

Growing Equity CushionEquity growth to ~1.50B in 2026 strengthens the balance sheet and provides capital buffer against shocks. A larger equity base supports borrowing capacity, reduces insolvency risk, and gives management room to fund strategic initiatives without immediate dilution.

Defensive Industry ExposureOperating in specialty and generic pharmaceuticals exposes the firm to durable demand and product lifecycles, regulatory barriers to entry, and recurring revenue from essential medicines. This structural positioning supports revenue stability and long-term relevance.

Bears Say

Weak Cash Flow QualityRepeated negative operating and free cash flows, including a sharp OCF drop to -109.8M and FCF -233.9M in 2026, signal that profits do not convert to cash reliably. This undermines internal funding for capex, R&D, or working capital and raises liquidity and refinancing risk.

Rising LeverageMaterial debt growth to ~499.6M increases fixed obligations while cash generation is weak. Higher leverage raises interest and refinancing vulnerability, constrains strategic flexibility, and could pressure credit metrics if cash flow performance does not improve.

Thin, Volatile Margins & Eroding Net IncomeDespite a recent revenue uptick, margins remain thin and net income has declined from 65.5M (2022) to ~39.7M (2026). This squeeze reduces internal cash available for growth, weakens returns on equity, and suggests competitive or cost pressures limiting durable earnings power.

AAREYDRUGS FAQ

What was Aarey Drugs & Pharmaceuticals Ltd.’s price range in the past 12 months?

Aarey Drugs & Pharmaceuticals Ltd. lowest stock price was ₹50.31 and its highest was ₹100.00 in the past 12 months.

What is Aarey Drugs & Pharmaceuticals Ltd.’s market cap?

Aarey Drugs & Pharmaceuticals Ltd.’s market cap is ₹2.18B.

When is Aarey Drugs & Pharmaceuticals Ltd.’s upcoming earnings report date?

Aarey Drugs & Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 19, 2026 which is in 66 days.

How were Aarey Drugs & Pharmaceuticals Ltd.’s earnings last quarter?

Aarey Drugs & Pharmaceuticals Ltd. released its earnings results on May 30, 2026. The company reported ₹0.55 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.55.

Is Aarey Drugs & Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Aarey Drugs & Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Aarey Drugs & Pharmaceuticals Ltd. pay dividends?

Aarey Drugs & Pharmaceuticals Ltd. pays a Notavailable dividend of ₹0.1 which represents an annual dividend yield of N/A. See more information on Aarey Drugs & Pharmaceuticals Ltd. dividends here

What is Aarey Drugs & Pharmaceuticals Ltd.’s EPS estimate?

Aarey Drugs & Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Aarey Drugs & Pharmaceuticals Ltd. have?

Aarey Drugs & Pharmaceuticals Ltd. has 28,354,303 shares outstanding.

What happened to Aarey Drugs & Pharmaceuticals Ltd.’s price movement after its last earnings report?

Aarey Drugs & Pharmaceuticals Ltd. reported an EPS of ₹0.55 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.754%.

Which hedge fund is a major shareholder of Aarey Drugs & Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:AAREYDRUGS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Aarey Drugs & Pharmaceuticals Ltd.

Aarey Drugs & Pharmaceuticals Limited, founded in 1990 and headquartered in Mumbai, India, specializes in the production and distribution of a wide array of chemical substances. The company manufactures active pharmaceutical ingredients (APIs), bulk drugs, chemical intermediates, and specialty chemicals, supplying various industrial sectors throughout India. Its pharmaceutical offerings include key APIs such as metformin HCL, mefenamic acid, and doxophylline, alongside uracile. Additionally, Aarey produces intermediates like mono and dimethyl urea, ortho para nitro anisole, and 2 bromomethyl 1,3 dioxalane. Beyond its core manufacturing, the firm provides a broad spectrum of chemicals and industrial solvents, encompassing aromatics, chemical acids, chlor-alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, chlorinated solvents, industrial alcohols, ketones, amines, oleochemicals, olefines, phosphates, fertilizers, and monomers. The company's pharmaceutical products are utilized by both pharmaceutical formulation manufacturers and merchant exporters. Furthermore, Aarey Drugs & Pharmaceuticals Limited actively participates in the trading of industrial solvents and other chemicals.